Sugi Predict

Sugi Predict / Compounds / SCHEMBL6092812

SCHEMBL6092812

SCHEMBL6092812

NCc1ccc2nccn2c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ KEAP1 Q14145 1/20 1.00
▸ DYRK1A Q13627 2/20 0.49
▸ MEN1 O00255 1/20 0.46
▸ CYP1A2 P05177 1/20 0.46
▸ KMT2A Q03164 1/20 0.46
▸ DAO P14920 1/20 0.44
▸ MERTK Q12866 6/20 0.43
▸ CPB2 Q96IY4 1/20 0.43
▸ RET P07949 1/20 0.42
▸ AXL P30530 5/20 0.41
▸ FLT3 P36888 5/20 0.41
▸ NAMPT P43490 4/20 0.40
▸ HDAC1 Q13547 1/20 0.40
▸ MET P08581 1/20 0.39
▸ PIK3CG P48736 1/20 0.38
▸ TYRO3 Q06418 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL17184538 0.98 KEAP1 (0.96) KEAP1DYRK1AMEN1CYP1A2KMT2A
Hydrochloric Acid SCHEMBL23201169 0.98 KEAP1 (0.96) KEAP1DYRK1AMEN1CYP1A2KMT2A
SCHEMBL74518 0.81 KEAP1 (0.68) KEAP1DYRK1AMEN1CYP1A2KMT2A
SCHEMBL14554770 0.81 KEAP1 (0.68) KEAP1DYRK1AMEN1CYP1A2KMT2A
SCHEMBL2049672 0.81 KEAP1 (0.68) KEAP1DYRK1AMEN1CYP1A2KMT2A
SCHEMBL24494597 0.81 KEAP1 (0.68) KEAP1DYRK1AMEN1CYP1A2KMT2A
SCHEMBL2535366 0.81 KEAP1 (0.68) KEAP1DYRK1AMEN1CYP1A2KMT2A
SCHEMBL14638413 0.81 KEAP1 (0.68) KEAP1DYRK1AMEN1CYP1A2KMT2A
SCHEMBL25804613 0.81 KEAP1 (0.68) KEAP1DYRK1AMEN1CYP1A2KMT2A
SCHEMBL19368821 0.80 KEAP1 (0.67) KEAP1DYRK1AMEN1CYP1A2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12486278-B2 MASP-2 inhibitors and methods of use OMEROS CORPORATION (US) 2025-12-02 — — US disclosed
US-12258365-B2 Organophosphorus-substituted compounds as c-MET inhibitors and therapeutic uses thereof BETA PHARMA, INC. (US) 2025-03-25 — — US disclosed
CN-115521305-B SHP2& NAMPT double-targeting compound, and pharmaceutical composition and application thereof 中国药科大学 2024-11-08 — — CN disclosed
EP-3893872-B1 ORGANOPHOSPHORUS-SUBSTITUTED COMPOUNDS AS C-MET INHIBITORS AND THERAPEUTIC USES THEREOF BETA PHARMA INC (US) 2024-07-17 — — EP disclosed
EP-4031547-B1 PLASMA KALLIKREIN INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICALS CO (JP) 2024-07-17 — — EP disclosed
EP-3893872-B1 ORGANOPHOSPHORUS-SUBSTITUTED COMPOUNDS AS C-MET INHIBITORS AND THERAPEUTIC USES THEREOF BETA PHARMA INC (US) 2024-07-17 — — EP disclosed
CN-113412112-B Organophosphorus substituted compounds as c-MET inhibitors and therapeutic uses thereof 贝达医药公司 2024-06-11 — — CN disclosed
WO-2024110608-A1 PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS NEURALIS (BE) 2024-05-30 — — WO disclosed
US-20240092788-A1 MASP-2 INHIBITORS AND METHODS OF USE OMEROS CORPORATION (US) 2024-03-21 — — US disclosed
WO-2024044098-A2 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-29 — — WO disclosed
WO-2013170112-A1 NAMPT INHIBITORS ABBVIE INC. (US) 2013-11-14 — — WO disclosed
US-8507487-B2 Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor HUTCHISON MEDIPHARMA LIMITED (CN) 2013-08-13 — — US disclosed
US-20120245178-A1 CERTAIN TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINES, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR HUTCHISON MEDIPHARMA LIMITED (CN) 2012-09-27 — — US disclosed
US-20120245178-A1 CERTAIN TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINES, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR HUTCHISON MEDIPHARMA LIMITED (CN) 2012-09-27 — — US disclosed
WO-2011079804-A1 CERTAIN TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINES, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR HUTCHISON MEDIPHARMA LIMITED (CN) 2011-07-07 — — WO disclosed
US-7112590-B2 Thrombin inhibitors LEK PHARMACEUTICALS D.D. (SI) 2006-09-26 — — US disclosed
EP-1287018-B1 THROMBIN INHIBITORS LEK TOVARNA FARMACEVTSKIH (SI) 2005-01-19 — — EP disclosed
US-20030191139-A1 Thrombin inhibitors UNIVERSITY OF LJUBLJANA (SI) 2003-10-09 — — US disclosed
EP-1287018-A2 THROMBIN INHIBITORS Lek Pharmaceutical and Chemical Co. D.D. (SI) 2003-03-05 — — EP disclosed
WO-2001085760-A1 THROMBIN INHIBITORS LEK PHARMACEUTICAL & CHEMICAL CO. DD (SI) 2001-11-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120245178-A1 CERTAIN TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINES, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR KCNJ11, NISCH, CYP4Z1 KEAP1 2417/4885DYRK1A 3409/4885MEN1 2879/4885
US-12486278-B2 MASP-2 inhibitors and methods of use MASP2, METAP2, SPINT2 KEAP1 1968/4885DYRK1A 3476/4885MEN1 150/4885
US-20030191139-A1 Thrombin inhibitors TFPI, F2, SERPINC1 KEAP1 1170/4885DYRK1A 2517/4885MEN1 1355/4885
US-20240092788-A1 MASP-2 INHIBITORS AND METHODS OF USE MASP2, METAP2, SPINT2 KEAP1 1968/4885DYRK1A 3476/4885MEN1 150/4885
US-12258365-B2 Organophosphorus-substituted compounds as c-MET inhibitors and therapeutic uses thereof MET, ALK, TYRO3 KEAP1 1859/4885DYRK1A 1063/4885MEN1 1220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.